Investigational drug · Phase 2
Camonsertib
Also called: RP-3500
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "Camonsertib"
First trial start
2020
Jul 22, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Camonsertib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Camonsertib" as an intervention, largest first.
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
Canadian Cancer Trials GroupResearch network
NCT05601440 · 484 participants (planned) · Start Jun 13, 2023 · Primary completion Dec 31, 2027
Drug: RP-6306; Gemcitabine and 6 more · For: Breast Cancer
Sites: Calgary, Canada; Kelowna, Canada; Vancouver, Canada · 10 sites in all
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03337698 · 314 participants · Start Dec 27, 2017 · Primary completion Oct 14, 2025
Drug: Atezolizumab; Cobimetinib and 15 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Las Vegas, Nevada; New York, New York; Cleveland, Ohio · 29 sites in all
Repare TherapeuticsIndustry
NCT04497116 · 276 participants · Start Jul 22, 2020 · Primary completion Jun 13, 2025
Drug: RP-3500 (camonsertib); Talazoparib and 1 more · For: Advanced Solid Tumor
Sites: Chicago, Illinois; Boston, Massachusetts; New York, New York · 13 sites in all
Repare TherapeuticsIndustry
NCT04972110 · 156 participants · Start Jul 21, 2021 · Primary completion Nov 13, 2024
Drug: RP-3500 (camonsertib) · For: Advanced Solid Tumor, Adult
Sites: Phoenix, Arizona; San Francisco, California; Aurora, Colorado · 13 sites in all
National Cancer Institute (NCI)NIH
NCT07156227 · 39 participants (planned) · Start Feb 13, 2027 · Primary completion May 31, 2029
Drug: Camonsertib · For: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma and 27 more
Sites: Duarte, California; Irvine, California; Lexington, Kentucky · 4 sites in all
Canadian Cancer Trials GroupResearch network
NCT05605509 · 28 participants · Start May 24, 2023 · Primary completion Nov 14, 2025
Drug: RP-6306; Gemcitabine and 3 more · For: Advanced Cancer
Sites: Kelowna, Canada; Vancouver, Canada; Kingston, Canada · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Bulk and single-cell transcriptomics for identification of potential diagnostic biomarkers associated with pulmonary arterial hypertension and integrated stress response and experimental validation.
Li H, Li M, Qiu C, et al. · Clin Exp Hypertens 2026
- Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.
Rosen EY, Yap TA, Fontana E, et al. · Clin Cancer Res 2026
- Targeting ATR and PI3Kα Pathways Promotes Ferroptosis in PIK3CA-Wildtype Platinum-Resistant Endometrial Cancer.
Shih CT, Ibanez KR, Lee JM, et al. · Cancers (Basel) 2026
- Recent advances in small molecule ATR kinase inhibitors as anticancer agents.
Singh G, Sharma R, Gautam V, et al. · Future Med Chem 2026
- Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts.
Jiang XT, Chen MK, Lee J, et al. · Sci Transl Med 2025
- Molecular architecture and inhibition mechanism of human ATR-ATRIP.
Wang G, Wang P, Zheng Z, et al. · Sci Bull (Beijing) 2025
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.